MiR-143-3p serves as a novel biomarker for diabetic cardiomyopathy and is involved in regulating high glucose-induced cardiomyocyte injury
Diabetes & Vascular Disease Research · 2026-07 · 23 (4)
DOI: 10.1177/14791641261454501 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes & Vascular Disease Research, online erschienen am 22.07.2026. Verfasst von Zhengnan Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Department, Geriatric Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Diabetic Cardiomyopathies, MicroRNAs, Myocytes, Cardiac, Glucose. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
This work aimed to verify the value of miR-143-3p in diabetic cardiomyopathy (DCM).
Methods
The ROC curve, correlation analysis, and multivariate Logistic regression analysis assessed the diagnostic value, association with DCM, and DCM risk factors. Bioinformatic analysis predicted the downstream targets of miR-143-3p. Dula-luciferase reporter assay validated the interaction between miR-143-3p and ERBB3. In vitro high glucose (HG)-stimulated cardiomyocyte (AC16) injury was employed to clarify the mechanism of the miR-143-3p/ERBB3 axis in DCM.
Results
Upregulation of miR-143-3p was observed in the DM group and further elevated in the DCM group compared with healthy individuals. The upregulated miR-143-3p expression distinguished subjects with DM from healthy individuals and diagnosed subjects with DCM from DM. MiR-143-3p expression was associated with blood glucose, myocardial injury, and cardiac function of DCM, and predicted the risk for DCM development. In vitro, the inhibition of miR-143-3p attenuated HG-induced AC16 cell injury through improving cell proliferation, suppressing apoptosis, inflammation, oxidative stress, and the release of myocardial enzymes by upregulating the ERBB3 expression.
Conclusions
Upregulation of miR-143-3p showed a diagnostic potential for DCM and predicted the progression of DCM. In vitro, miR-143-3p promoted HG-induced cardiomyocyte injury by targeting ERBB3, which might provide novel insights for DCM clinical management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Department, Geriatric Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China.
- Cardiology Department, Wuxi Hospital of Traditional Chinese Medicine Wuxi, China.
- Department of Endocrinology, Huaihe Hospital of Henan University, Kaifeng, China.
- Department of Cardiology, Baoji Hospital of Traditional Chinese Medicine, Baoji, China.
- Department of Emergency, Taikang Tongji (Wuhan) Hospital, Wuhan, China.
ORCID-Profile: Yang Bian
Zitieren
APA
Zhang, Z., Wang, S., Zhu, L., Bian, Y., & Zhao, J. (2026). MiR-143-3p serves as a novel biomarker for diabetic cardiomyopathy and is involved in regulating high glucose-induced cardiomyocyte injury. Diabetes & Vascular Disease Research, 23(4). https://doi.org/10.1177/14791641261454501
Vancouver
Zhang Z, Wang S, Zhu L, Bian Y, Zhao J. MiR-143-3p serves as a novel biomarker for diabetic cardiomyopathy and is involved in regulating high glucose-induced cardiomyocyte injury. Diabetes & Vascular Disease Research. 2026;23(4). doi:10.1177/14791641261454501
BibTeX
@article{Zhang2026,
author = {Zhang, Zhengnan and Wang, Suyun and Zhu, Liping and Bian, Yang and Zhao, Jing},
title = {MiR-143-3p serves as a novel biomarker for diabetic cardiomyopathy and is involved in regulating high glucose-induced cardiomyocyte injury},
journal = {Diabetes & Vascular Disease Research},
year = {2026},
volume = {23},
number = {4},
doi = {10.1177/14791641261454501}
}
EUVIMED